Monopar Therapeutics Inc. (NASDAQ:MNPR) Sees Large Growth in Short Interest

Monopar Therapeutics Inc. (NASDAQ:MNPR - Get Free Report) was the target of a significant growth in short interest in February. As of February 28th, there was short interest totalling 51,300 shares, a growth of 57.8% from the February 13th total of 32,500 shares. Currently, 1.3% of the shares of the stock are short sold. Based on an average trading volume of 66,900 shares, the days-to-cover ratio is currently 0.8 days.

Analysts Set New Price Targets

A number of research firms recently commented on MNPR. HC Wainwright lifted their price objective on Monopar Therapeutics from $22.00 to $40.00 and gave the stock a "buy" rating in a research report on Wednesday, January 22nd. Piper Sandler started coverage on shares of Monopar Therapeutics in a research note on Friday, January 10th. They set an "overweight" rating and a $72.00 price target on the stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. JPMorgan Chase & Co. acquired a new position in Monopar Therapeutics in the fourth quarter valued at $45,000. Geode Capital Management LLC raised its holdings in shares of Monopar Therapeutics by 174.4% in the 4th quarter. Geode Capital Management LLC now owns 38,596 shares of the company's stock worth $849,000 after purchasing an additional 24,530 shares during the period. ADAR1 Capital Management LLC acquired a new position in shares of Monopar Therapeutics in the 4th quarter valued at about $2,861,000. Adage Capital Partners GP L.L.C. purchased a new stake in shares of Monopar Therapeutics during the 4th quarter worth about $13,182,000. Finally, RA Capital Management L.P. purchased a new stake in shares of Monopar Therapeutics during the 4th quarter worth about $11,247,000. Institutional investors and hedge funds own 1.83% of the company's stock.

Remove Ads

Monopar Therapeutics Stock Up 15.1 %

Shares of MNPR stock traded up $4.48 during mid-day trading on Monday, hitting $34.23. 22,846 shares of the company's stock were exchanged, compared to its average volume of 360,360. The stock has a market cap of $208.87 million, a price-to-earnings ratio of -17.38 and a beta of 1.18. Monopar Therapeutics has a fifty-two week low of $1.72 and a fifty-two week high of $54.30. The stock has a 50-day simple moving average of $35.77 and a two-hundred day simple moving average of $21.54.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.